Stress cardiomyopathy in patients with central nervous system disease
Authors:
M. Bílská- 1 4; I. Vitvarová 1; ; M. Vojtíšek 5; J. Hlaváček 5; J. Stelmach 1; V. Černý- 1,4,6 8; D. Astapenko 2,8; R. Škulec 1,4,9
Authors‘ workplace:
Klinika anesteziologie, perioperační, a intenzivní medicíny Fakulty zdravotnických studií Univerzity J. E. Purkyně, v Ústí nad Labem a Krajské zdravotní, a. s. – Masarykovy nemocnice, v Ústí nad Labem, o. z.
1; LF UK v Hradci Králové
2; Zdravotnická záchranná služba Ústeckého kraje, Ústí nad Labem
3; Fakulta zdravotnických studií, Univerzita J. E. Purkyně v Ústí nad Labem
4; Kardiologická klinika Fakulty zdravotnických studií Univerzity J. E. Purkyně, v Ústí nad Labem a Krajské zdravotní, a. s. – Masarykovy nemocnice, v Ústí nad Labem, o. z.
5; Ústav klinických oborů a biomedicíny, Technická univerzita v Liberci
6; Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada
7; Klinika anesteziologie, resuscitace a intenzivní medicíny FN Hradec Králové
8; Nemocnica Bory, Penta Hospitals, Bratislava, Slovensko
9
Published in:
Cesk Slov Neurol N 2025; 88(1): 15-21
Category:
Review Article
doi:
https://doi.org/10.48095/cccsnn202515
Overview
Stress cardiomyopathy stands for a clinical syndrome characterized by the onset of myocardial dysfunction caused by stressful event. A common trigger is neurological disease, most commonly non-traumatic subarachnoid hemorrhage and ischemic stroke. The development of stress cardiomyopathy may cause arterial hypotension, arrhythmias, or acute heart failure in these patients. Despite the reversibility of the disease, its secondary form is particularly dangerous because of the risk of developing serious complications. Causal treatment focuses on eliminating the cause; further therapy is symptomatic, guided by echocardiographic findings. The aim of this review article is to summarize the current knowledge regarding stress cardiomyopathy focusing on up- -to-date diagnostics and treatment and highlight their differences in patients with neurological disease.
Keywords:
acute coronary syndrome – ischemic stroke – stress cardiomyopathy – subarachnoid hemorrhage – takotsubo
Sources
1. Ghadri JR, Wittstein IS, Prasad A et al. International expert consensus document on takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018; 39 (22): 2032–2046. doi: 10.1093/eurheartj/ehy076.
2. Medina de Chazal H, del Buono MG, Keyser-Marcus L et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72 (16): 1955–1971. doi: 10.1016/j.jacc.2018.07.072.
3. Baker C, Muse J, Taussky P. Takotsubo syndrome in neurologic disease. World Neurosurg 2021; 149: 26–31. doi: 10.1016/j.wneu.2021.01.139.
4. Otten AM, Ottervanger JP, Symersky T et al. Diagnosis of takotsubo cardiomyopathy is increasing over time in patients presenting as ST-elevation myocardial infarction. Neth Heart J 2016; 24 (9): 520–529. doi: 10.1007/s12471-016-0859-x.
5. Bairashevskaia AV, Belogubova SY, Kondratiuk MR et al. Update of Takotsubo cardiomyopathy: present experience and outlook for the future. Int J Cardiol Heart Vasc 2022; 39: 100990. doi: 10.1016/j.ijcha.2022. 100990.
6. Brazdil V, Kala P, Hudec M et al. The role of central autonomic nervous system dysfunction in Takotsubo syndrome: a systematic review. Clin Auton Res 2022; 32 (1): 9–17. doi: 10.1007/s10286-021-00844-z.
7. Klein C, Hiestand T, Ghadri JR et al. Takotsubo syndrome – predictable from brain imaging data. Sci Rep 2017; 7 (1): 5434. doi: 10.1038/s41598-017-05592-7.
8. Sposato LA, Hilz MJ, Aspberg S et al. Post-stroke cardiovascular complications and neurogenic cardiac injury: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76 (23): 2768–2785. doi: 10.1016/j.jacc.2020.10.009.
9. Chen Z, Venkat P, Seyfried D et al. Brain-heart interaction: Cardiac Complications After Stroke. Circ Res 2017; 121 (4): 451–468. doi: 10.1161/CIRCRESAHA.117. 311170.
10. Buchmann SJ, Lehmann D, Stevens CE. Takotsubo cardiomyopathy-acute cardiac dysfunction associated with neurological and psychiatric disorders. Front Neurol 2019; 10: 917. doi: 10.3389/fneur.2019.00917.
11. Galiuto L, Crea F. Primary and secondary takotsubo syndrome: pathophysiological determinant and prognosis. Eur Heart J Acute Cardiovasc Care 2020; 9 (7): 690–693. doi: 10.1177/2048872620963493.
12. Ghadri JR, Sarcon A, Diekmann J et al. Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. Eur Heart J 2016; 37 (37): 2823–2829. doi: 10.1093/eurheartj/ehv757.
13. Elikowski W, Małek-Elikowska M, Różańska P et al. Isolated right ventricular takotsubo cardiomyopathy: a case report and literature review. Pol Merkur Lekarski 2016; 41 (246): 283–286.
14. Szántó D, Luterán P, Gál J et al. Diagnosis and management of Takotsubo syndrome in acute aneurysmal subarachnoid hemorrhage: a comprehensive Review. Rev Cardiovasc Med 2023; 24 (6): 177. doi: 10.31083/ j.rcm2406177.
15. Dostálová V, Hosszú T, Solař M et al. Takotsubo syndrom v průběhu spondylochirurgického výkonu. Anest Intenziv Med 2019; 30 (3–4): 126–129. doi: 10.36290/aim.2019.043.
16. Bilska M, Skulec R, Stadlerova B et al. Stresové kardiomyopatie – kazuistiky. Urgentní medicína 2021; 3: 12–15.
17. Maher M, Schweizer TA, Macdonald RL. Treatment of spontaneous subarachnoid hemorrhage: guidelines and gaps. Stroke 2020; 51 (4): 1326–1332. doi: 10.1161/ STROKEAHA.119.025997.
18. Chung DY, Abdalkader M, Nguyen TN. Aneurysmal subarachnoid hemorrhage. Neurol Clin 2021; 39 (2): 419–442. doi: 10.1016/j.ncl.2021.02.006.
19. Ghadri JR, Wittstein IS, Prasad A et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J 2018; 39 (22): 2047–2062. doi: 10.1093/eurheartj/ehy077.
20. Lyon AR, Bossone E, Schneider B et al. Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2016; 18 (1): 8–27. doi: 10.1002/ejhf.424.
21. Arbelo E, Protonotarios A, Gimeno JR et al 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44 (37): 3503–3626. doi: 10.1093/eurheartj/ehad194.
22. Madias JE. Takotsubo cardiomyopathy: current treatment. J Clin Med 2021; 10 (15): 3440. doi: 10.3390/jcm10153440.
23. Kawano H, Yamasa T, Arakawa S et al. Landiolol dramatically improved Takotsubo cardiomyopathy in an older patient. Geriatr Gerontol Int 2017; 17: 2622–2623. doi: 10.1111/GGI.13162.
24. Santoro F, Ieva R, Ferraretti A et al. Hemodynamic effects, safety, and feasibility of intravenous esmolol infusion during Takotsubo cardiomyopathy with left ventricular outflow tract obstruction: results from a multicenter registry. Cardiovasc Ther 2016; 34 (3): 161–166. doi: 10.1111/1755-5922.12182.
25. Santoro F, Ieva R, Ferraretti A et al. Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series. Cardiovasc Ther 2013; 31 (6): e133–e137. doi: 10.1111/1755-5922. 12047.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2025 Issue 1
Most read in this issue
- Guidelines of the Cerebrovascular Section of the Czech Neurological Society of the CMA JEP and the Czech Society for Interventional Radiology of the CMA JEP for the indication of mechanical recanalization – version 2024
- Idiopathic orofacial pain
- Options for the use of epidural stimulation in individuals with motor complete spinal cord injury
- Normative data of the Montreal Cognitive Assessment for the blind (MoCA-22) for the Czech population